Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Daniel E. Everitt"'
Autor:
Gisela Torres, Eiko Toichi, Thomas S. McCormick, Kevin D. Cooper, Daniel E. Everitt, Mary Ann Mascelli, Bart Frederick, Catharine L. Kauffman, Timothy Chang, Charles Pendley, Nancy Aria, Alice B. Gottlieb
Publikováno v:
The Journal of Immunology. 177:4917-4926
Psoriasis is characterized by activation of T cells with a type 1 cytokine profile. IL-12 and IL-23 produced by APCs are essential for inducing Th1 effector cells. Promising clinical results of administration of an Ab specific for the p40 subunit of
Autor:
Bart Frederick, Daniel E. Everitt, Mary Ann Mascelli, Yaowei Zhu, Charles Pendley, Alice B. Gottlieb, Martin A. Graham, Kevin D. Cooper, Nancy Aria, Thomas S. McCormick, Eiko Toichi, Catharine L. Kauffman
Publikováno v:
Journal of Investigative Dermatology. 123:1037-1044
The potential therapeutic activity of a human monoclonal antibody to the human interleukin-12 p40 subunit (anti-IL-12p40) has been established both in vitro and in vivo, warranting a first-in-human investigation in psoriasis. This phase I, first-in-h
Autor:
Mark Monane, Alexander M. Walker, Jerry Avorn, Jerry H. Gurwitz, Rhonda L. Bohn, Helen Mogun, Daniel E. Everitt
Publikováno v:
The American Journal of Medicine. 99:48-54
PURPOSE : Despite the widespread use of neuroleptic medications for the elderly, little is known about the frequency of treatment for drug-induced parkinsonian syndromes in this age group, particularly with L-dopa-type drugs, which are more appropria
Autor:
Daniel E. Everitt, Norman Gevitz
Publikováno v:
The Journal of Medical Humanities. 15:255-258
Autor:
Mark Monane, Robert J. Glynn, Nancy Smith, Jerry Avorn, Daniel E. Everitt, Jerry H. Gurwitz, Daniel Gilden
Publikováno v:
American Journal of Public Health. 83:711-716
OBJECTIVES. The purpose of this study was to determine the extent of nonadherence to treatment for glaucoma among elderly patients. METHODS. This was a retrospective cohort study of 2440 patients older than age 65 who were enrolled in the New Jersey
Autor:
David R. Sherman, Dennis Ross-Degnan, Stephen B. Soumerai, Daniel E. Everitt, Susanne Salem-Schatz, Mark H. Beers, David Fields, Jerry Avorn
Publikováno v:
New England Journal of Medicine. 327:168-173
Although psychoactive medications have substantial side effects in the elderly, these drugs are used frequently in nursing homes. Few interventions have succeeded in changing this situation, and little is known about the clinical effects of such inte
Autor:
Roselie A. Bright, Daniel E. Everitt
Publikováno v:
JAMA: The Journal of the American Medical Association. 267:1783-1787
Objective. —To evaluate the relationship between β-blockers and depression. Design. —Case-control study. Setting. —New Jersey Medicaid recipients during July 1980 to December 1983. Participants. —New depression case patients (N = 4302) were
Publikováno v:
The American Journal of Medicine. 89:357-362
We interviewed a representative random sample of 501 office-based general physicians and 298 nurse practitioners to evaluate their approach to the symptoms of insomnia. Clinicians were presented with a standard case of a patient complaining of diffic
Autor:
Kevin D. Cooper, Yaowei Zhu, Charles Pendley, Bart Frederick, Alice B. Gottlieb, Martin A. Graham, Thomas S. McCormick, Daniel E. Everitt, Mary Ann Mascelli, Eiko Toichi
Publikováno v:
Current medical research and opinion. 23(5)
To evaluate safety, pharmacokinetics, pharmacodynamics, and clinical response of single subcutaneous (s.c.) administrations of a human monoclonal antibody against the p40 subunit of IL-12/23 (IL-12/23 mAb) in subjects with moderate-to-severe psoriasi
Autor:
Mary Ann Mascelli, Timothy Vollmer, Daniel E. Everitt, Thomas Leist, Aparna Raychaudhuri, Kenneth P. Johnson, Kathleen A. Ryan, Lloyd H. Kasper
Publikováno v:
Current medical research and opinion. 22(9)
To assess the safety, tolerability and pharmacokinetics of an interleukin (IL)-12/23 monoclonal antibody (mAb) in subjects with a relapsing form of multiple sclerosis (MS).A phase I, double-blind, placebo-controlled, sequential dose escalation study